Table 1

Main characteristics of all studies included in the meta-analysis
Study Country Sample/Female Treatment Colon/rectum (n) Lymph node metastasis (no/yes, n) Tumor size (cm) : (n) TNM stage Follow-up in months S100A4 assay Cut-off for high expression High S100A4 expression: n (%) Outcome
Gongoll, 2002 [17] Germany 709/296 Surgery 318/391 606/103 <2: 42 2–5: 440 >5: 227 I/II: 218 NR IHC > 50% cancer cells stained 114 (16.1) OS, Clinicopathological parameters
III/IV: 491
Boye, 2010 [21] Norway 242/110 Mixed 163/79 185/57 NR I/II: 165 Median 109, range 98–120 IHC Nuclear cancer cells staining positive 73 (30.2) OS, DFS
III: 77
Kwak, 2010 [22] South Korea 127/51 Surgery 55/72 73/54 NR I/II: 73 Median 58.7, range 1.1-101.8 IHC 20% of tumor cells stained 45 (35.4) OS, Clinicopathological parameters
III/IV: 54
Wang, 2010 [23] China 115/52 Surgery 77/38 97/18 NR NR Median 62, range 4-76 IHC ≥ 20% tumor cells stained 66 (57.4) OS, Clinicopathological parameters
Huang, 2011 [24] China 112/53 Surgery 47/65 59/53 ≤5: 74; >5: 38 I/II: 57 NR IHC > 35% cancer cells stained 57 (50.9) OS, Clinicopathological parameters
III/IV: 55
Kang, 2012 [26] Korea 526/204 Surgery 321/205 255/271 NR NR Median 40.1, range 2–69 IHC 30% of tumor cells stained, 136 (25.9) OS, Clinicopathological parameters
Kho, 2012 [27] Australia 409/159 Mixed 451/0 NR < 5: 205 ≥ 5: 204 I/II: 256 Median 34.6, range 0.4-351 IHC ≥ 50% cancer cells stained 45 (11.0) OS, Clinicopathological parameters
III/IV: 133
Lee, 2013 [29] Korea 333/144 Surgery NR 240/93 NR I/II: 187 At least 5 years IHC Stained cells were grade one 267 (50.0) OS, DFS, Clinicopathological parameters
III/IV:146
Stein, 2011 [25] Germany 375/205 Mixed 185/190 341/34 NR I/II: 139 Median 24.3 RT-PCR 0.387 S100A4 143 (49.7) DFS
III/IV: 61 mRNA expression,% calibrator
Cho, 2005 [18] South Korea 124/NR Surgery NS 59/65 <5: 57 NR Rang 14–38 IHC > 30% cancer cells stained 69 (55.6) Clinicopathological parameters
≥ 5: 67
Hemandas, 2006 [19] Singapore 54/23 Mixed 34/20 46/8 <2: 5 NR Median 65, rang 3– 104 IHC > 20% cancer cells stained 28 (51.9) Clinicopathological parameters
2-5: 31 >5: 18
Kim, 2009 [20] Korea 73/40 Surgery 38/35 65/8 ≤ 2: 4 NR NR IHC > 20% cancer cells stained 40 (54.8) Clinicopathological parameters
2-5: 38
≥ 5: 31
Giraldez, 2013 [28] Spain 228/95 CHT 228/0 NR NR II: 78 Median 42, RT-PCR Risk score: 4.076 NR Clinicopathological parameters
III: 150 Range 6–152

NR = no report; Treatment: Mixed = surgery plus chemotherapy; OS = overall survival; DFS = disease-free survival; IHC = immunochemistry; RT-PCR = reverse-transcription-polymerase chain reaction; CHT = chemotherapy.

Liu et al.

Liu et al. Diagnostic Pathology 2013 8:181   doi:10.1186/1746-1596-8-181

Open Data